Clinical Trial

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2026-12 2026-07-24
minor Completion pushed: 2026-07 -> 2028-06 2026-07-24
Trial Details
NCT Number NCT06471205
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Triple-negative Breast Cancer
Enrollment 52 participants
Start Date 2024-08-02
Primary Completion 2026-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-23